Corrigendum: Bazi Bushen Capsule Alleviates Post-Menopausal Atherosclerosis via GPER1-Dependent Anti-Inflammatory and Anti-Apoptotic Effects

Huang, Dan; Wang, Xindong; Yunhong, Zhu; Gong, Jin; Liang, Jing; Song, Yanfei; Zhang, Yiyan; Liu, Linsheng; Cong, Wei

doi:10.3389/fphar.2021.774792

Cited by 7 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bazi Bushen capsule (BZBS) comprises 16 Chinese medicines (Huang et al. 2021 ) and is highly effective at relieving fatigue, curing impotence and male infertility, tonifying the kidneys, and delaying the ageing process in clinical studies (Huang et al. 2021 ; Li et al.…”

Section: Introductionmentioning

confidence: 99%

“…Chemical analysis has identified 14 unique substances in BZBS by ultra-performance liquid chromatography/mass spectrometry (UPLC/MS) (Huang et al. 2021 ; Figure 1 , Table 1 ). These include chlorogenic acids, flavonoids, phenylethanoid glycosides, coumarins, lignans and terpenoid catalpol, which contain a variety of anti-ageing natural plant components and protect against age-related cognitive deficits (Wei et al.…”

Section: Introductionmentioning

confidence: 99%

“… 2020 ) and treating post-menopausal atherosclerosis in ovariectomized female Ovx/ApoE–/– mice (Huang et al. 2021 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bazi Bushen capsule attenuates cognitive deficits by inhibiting microglia activation and cellular senescence

Shen

et al. 2022

Pharmaceutical Biology

View full text Add to dashboard Cite

Context Bazi Bushen capsule (BZBS) has anti-ageing properties and is effective in enhancing memory. Objective To find evidence supporting the mechanisms and biomarkers by which BZBS functions. Materials and methods Male C57BL/6J mice were randomly divided into five groups: normal, ageing, β-nicotinamide mononucleotide capsule (NMN), BZBS low-dose (LD-BZ) and BZBS high-dose (HD-BZ). The last four groups were subcutaneously injected with d -galactose ( d -gal, 100 mg/kg/d) to induce the ageing process. At the same time, the LD-BZ, HD-BZ and NMN groups were intragastrically injected with BZBS (1 and 2 g/kg/d) and NMN (100 mg/kg/d) for treatment, respectively. After 60 days, the changes in overall ageing status, brain neuron morphology, expression of p16 INK4a , proliferating cell nuclear antigen (PCNA), ionized calcium-binding adapter molecule 1 (Iba1), postsynaptic density protein 95 (PSD95), CD11b, Arg1, CD206, Trem2, Ym1 and Fizz1, and the senescence-associated secretory phenotype (SASP) factors were observed. Results Compared with the mice in the ageing group, the HD-BZ mice exhibited obvious improvements in strength, endurance, motor coordination, cognitive function and neuron injury. The results showed a decrease in p16 INK4a , Iba1 and the upregulation of PCNA, PSD95 among brain proteins. The brain mRNA exhibited downregulation of Iba1 ( p < 0.001), CD11b ( p < 0.001), and upregulation of Arg1 ( p < 0.01), CD206 ( p < 0.05), Trem2 ( p < 0.001), Ym1 ( p < 0.01), Fizz1 ( p < 0.05) and PSD95 ( p < 0.01), as well as improvement of SASP factors. Conclusions BZBS improves cognitive deficits via inhibition of cellular senescence and microglia activation. This study provides experimental evidence for the wide application of BZBS in clinical practice for cognitive deficits.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%